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Abstract
 Background—Liver disease is a major cause of mortality among HIV-infected persons. There 
is limited information about the extent to which HIV disease severity impacts liver disease 
progression.
 Methods—We determined the incidence and predictors of advanced hepatic fibrosis measured 
by the FIB-4 index (≥3.25) in a large diverse population of HIV-infected patients without 
significant liver disease at baseline (FIB-4<1.45) in care between January 2000 and March 2014. 
We used Cox proportional hazards analysis to examine factors associated with progression to 
FIB-4 ≥3.25.
 Results—Among 14,198 HIV-infected patients, HCV coinfection (adjusted hazard ratio [aHR] 
1.9, 95% CI 1.6–2.1), HBV coinfection (aHR 1.5, 95% CI 1.2–1.8), alcohol use disorder (aHR 1.4, 
95% CI 1.2–1.6) and diabetes (aHR 1.9, 95% CI 1.6–2.3) were associated with progression to 
advanced fibrosis in multivariable analysis. In addition, patients at each lower level of time-
varying CD4 count had a significantly greater risk of progression, with a nearly 7-fold higher risk 
in those with CD4 <100 cells/mm3 (aHR 6.9, 95% CI 5.8–8.3) compared with CD4 ≥500 cells/
mm3. An increasing gradient of risk was also observed among patients with higher time-varying 
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HIV viral load (VL), with the greatest risk noted with VL ≥100,000 copies/ml (aHR 2.6, 95% CI 
2.2–3.1) compared with VL <500 copies/ml.
 Conclusion—Lower CD4 count and higher HIV VL were significantly associated with 
progression to advanced hepatic fibrosis in a dose-dependent manner, independent of the risk 
associated with traditional factors: HCV or HBV coinfection, alcohol, and diabetes. Our findings 
suggest that early treatment of HIV infection could mitigate liver disease.
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 Introduction
Liver disease has emerged as a major cause of morbidity and mortality among HIV-infected 
individuals with the improvement in overall survival since the introduction of effective 
combination antiretroviral therapy (ART),. While chronic hepatitis C virus (HCV) may 
account for much of this mortality,, an excess burden of liver disease has been reported in 
HIV monoinfected patients.– Multiple studies have demonstrated accelerated progression to 
cirrhosis in HIV-HCV coinfected patients compared with HCV-monoinfected patients, and 
that ART mitigates the progression of liver disease in coinfected patients.– However, our 
current understanding of the clinical course of hepatic fibrosis is derived primarily from 
single-center studies of HIV-HCV coinfected patients with limited size and follow-up. 
Progression of liver disease in HIV monoinfected patients has not been well characterized 
and little is known about the extent to which HIV disease severity influences liver disease 
progression, particularly early in the disease course when interventions may have the 
greatest impact.
We conducted this study to define the incidence and predictors of progression to advanced 
hepatic fibrosis measured by the Fibrosis-4 (FIB-4) index in a well-characterized multicenter 
cohort of HIV-infected patients with minimal or no fibrosis at baseline. The FIB-4 index, 
which has been validated in a variety of settings, correlates with histologic stages of fibrosis,
and unlike liver biopsy, is routinely measured at multiple time points. FIB-4 ≥3.25 is a well-
validated threshold shown to be predictive not only of advanced fibrosis, but also of liver-
related clinical outcomes and overall mortality., Accounting for multiple risk factors for 
fibrosis, we sought to determine the role of HIV disease severity in the progression of liver 
disease among those with and without viral hepatitis.
 Methods
 Data Source & Study Population
The Center for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort is a 
dynamic prospective clinical cohort of HIV-infected adults receiving care at eight 
participating academic sites across the US. Comprehensive clinical data including diagnoses, 
medications, laboratory, and demographic information collected through electronic medical 
records and other institutional data systems at each site are harmonized in the CNICS data 
repository. Data from each site are updated, undergo extensive quality assurance procedures, 
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and integrated in the repository quarterly (http://www.uab.edu/cnics). Institutional review 
boards at each site approved the study protocol.
All patients who entered the cohort on or after January 1, 2000, had a minimum of two 
FIB-4 scores and six months of follow-up, and a baseline FIB-4 score <1.45 which is below 
the threshold of significant fibrosis (comparable to METAVIR stage 0–1 fibrosis), were 
included in this study.
 Independent Variables
Patients were categorized according to their age at study entry, race/ethnicity classified as 
white (non-Hispanic), black (non-Hispanic), Hispanic and other/unknown, and history of 
injection drug use reported as a risk factor for HIV transmission. Additional baseline 
characteristics documented within six months of entry into the cohort included FIB-4; HCV 
coinfection defined as a detectable HCV RNA level, HCV genotype or HCV antibody; 
hepatitis B (HBV) coinfection defined as a positive hepatitis B surface antigen or detectable 
HBV DNA level; and body mass index (BMI) defined as underweight (<18.5 kg/m2), 
overweight (25–29 kg/m2) and obese (≥30 kg/m2) using the normal range (18.5 to <25 
kg/m2) as the referent category. Alcohol use disorder was defined as a diagnosis of alcohol 
abuse or dependence recorded by the treating clinician based on a modified list of 
International Classification of Diseases, Ninth Revision [ICD-9] diagnostic codes (291.x, 
303.x and 305.0) shown to be highly specific and moderately sensitive for alcohol use 
disorder in other settings., Diabetes mellitus was defined as an ICD-9 diagnosis of diabetes 
mellitus and use of diabetes-related medication, use of diabetes-specific medication, or a 
hemoglobin A1C ≥ 6.5%; CD4 cell count was categorized as ≥500, 350–500, 200–349, 100–
199, <100 cells/mm3, and HIV viral load (VL) was classified as <500, 500–999, 10,000–
99,999 and ≥100,000 copies/ml.
 Outcome Measure
The primary endpoint was progression of liver disease to FIB-4 greater than or equal to 3.25. 
We computed the FIB-4 index using the formula: FIB-4 = (age [years]×AST [U/L]) / 
(platelet count [109/L]×(ALT [U/L])1/2) and the closest platelet count to within a year of the 
date of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) testing, which 
occurred on the same day in over 92% of patients. In secondary analysis, we also examined 
the AST-platelet ratio index (APRI) as another noninvasive endpoint measuring hepatic 
fibrosis, using the formula: APRI = (AST [U/L] / upper limit of normal for AST (or 40 
U/L))×100 / platelet count [109/L]. Advanced fibrosis was defined as APRI greater than 1.5.
 Statistical Analysis
We calculated incidence rates and 95% confidence intervals for progression to FIB-4 ≥3.25. 
Follow-up began at the first FIB-4 measurement more than six months after a patient’s first 
visit to allow for full ascertainment of baseline characteristics, and continued until the study 
endpoint, last available FIB-4 measurement, or administrative censoring on March 30, 2014, 
whichever occurred first.
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We used a Cox proportional hazards model to estimate the relative hazards of FIB-4 
progression. In addition to CD4 cell count and HIV VL, we included variables reported to be 
risk factors for liver-related outcomes in HIV-infected or HIV-HCV coinfected patients,: sex, 
race, HCV coinfection, HBV coinfection, and alcohol use disorder, and diabetes mellitus. 
CD4 cell count, HIV VL and diabetes were modeled as time-varying covariates. In the 
multivariable analysis, we adjusted for baseline FIB-4 modeled as a continuous variable and 
stratified by HCV status. We did not include age in our multivariable model since it is a 
component of the FIB-4 index, or HIV transmission risk factor due to collinearity between 
injection drug use and HCV infection. We repeated these models using APRI >1.5 as the 
outcome and included age as a separate covariate.
In secondary analyses, we assessed the interactions between CD4 count (CD4<200 
cells/mm3 / CD4≥200 cells/mm3) and HIV VL (<500 copies/ml / ≥500 copies/ml), and 
between alcohol use disorder and HCV as dichotomous variables in the FIB-4 model. We 
included baseline BMI as a covariate in the full model to evaluate whether the effect of 
diabetes on FIB-4 progression was changed by the addition of BMI. We evaluated the 
impact of ART-mediated HIV viral suppression (<500 copies/ml) as a time-varying factor in 
a separate analysis. We stratified our model by platelet count level based on the distribution 
in our cohort (<220×109 cells/L, 220–269×109 cells/L and ≥270×109 cells/L) to examine 
whether HIV-associated thrombocytopenia influenced our findings. All analyses were 
performed using Stata 13 (College Station, TX).
 Results
Between January 1, 2000 and March 31, 2014, 20,185 HIV-infected individuals initiated 
care in CNICS and had at least two FIB-4 measurements. Among these patients, 5,987 
(29%) had a baseline FIB-4 ≥1.45 and were excluded from the analysis, resulting in a total 
of 14,198 patients in the study cohort. As shown in Table 1, the majority of the cohort was 
male (82%) with sex with men as a risk factor for HIV transmission (58%) and a median age 
of 38 years. The cohort was racially/ethnically diverse with 46% white/non-Hispanic, 34% 
black/non-Hispanic and 14% Hispanic. The prevalence of hepatitis C coinfection was 12%, 
and alcohol use disorder was identified in 9%. The median baseline FIB-4 score was 0.8 
(interquartile range [IQR], 0.6–1.0).
 Progression to Advanced Fibrosis
Progression to advanced fibrosis occurred in 1,386 patients (9.7%) in a median of 3 years 
(interquartile range [IQR] 1.2–5) during a total of 61,904 person-years of follow-up (PYFU) 
for an overall incidence of 2.2 per 100 PYFU (95% confidence interval [CI] 2.1–2.4). The 
incidence of advanced fibrosis was 4.7 per 100 PYFU (95% CI 4.2–5.3) among HIV-HCV 
coinfected patients compared with 1.9 per 100 PYFU (95% CI 1.8–2.0) among HIV 
monoinfected patients.
The median FIB-4 at the end of follow-up among patients who progressed to advanced 
fibrosis was 4.2 (IQR 3.6–5.7). Compared to patients who had not progressed to advanced 
fibrosis, those who progressed were more likely to be black (41% vs. 34%), have a history of 
injection drug use (20% vs. 11%), HCV coinfection (24% vs. 10%), HBV coinfection (6% 
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vs. 3%), diabetes (5% vs. 4%), and a history of alcohol use disorder (14% vs. 9%), P<0.01 
for all comparisons (Table 1). Patients who progressed to advanced fibrosis were also more 
likely to have a CD4 count less than 200 cells/mm3 (31% vs. 16%, P<0.001) and detectable 
HIV VL ≥500 copies/ml (53% vs. 38%, P<0.001) at baseline as well as at the end of follow-
up, at which time only 52% of patients who progressed were virally suppressed compared 
with 79% of non-progressors, P<0.001.
 Risk Factors for Liver Disease Progression
In multivariable analysis, HCV coinfection (adjusted hazard ratio [aHR] 1.9, 95% CI 1.6–
2.1), HBV coinfection (aHR 1.5, 95% CI 1.2–1.8), alcohol use disorder (aHR 1.4, 95% CI 
1.2–1.6) and diabetes (aHR 1.9, 95% CI 1.6–2.3) were significantly associated with 
progression to advanced fibrosis, while race and sex were not (Table 2). In addition, each 
lower level of CD4 count was independently associated with progression to advanced 
fibrosis, with the greatest risk of progression observed in patients with the lowest CD4 
count. An increasing gradient of risk was also observed among patients with higher time-
varying HIV VL, with HIV VL ≥100,000 copies/ml carrying the greatest risk of progression. 
Patients with CD4 count <100 cells/mm3 had a nearly 7-fold higher risk of progression 
(aHR 6.9, 95% CI 5.8–8.3) compared with patients with CD4 count ≥500 cells/mm3. 
Similarly, patients with HIV VL ≥100,000 copies/ml had an aHR of 2.6 compared with 
those who were virally suppressed (95% CI 2.2–3.1). After controlling for other factors, 
time-updated viral suppression had an independent protective effect against progression to 
advanced fibrosis (aHR 0.6, 95% CI 0.6–0.7).
We observed comparable findings for both HIV monoinfected patients and HIV-HCV 
coinfected patients in stratified analyses as shown in Table 2. Alcohol use disorder, lower 
CD4 count and higher HIV VL were independent predictors of advanced fibrosis in both 
monoinfected and coinfected patients. The association between chronic HBV infection, 
diabetes and the less severe categories of CD4 count (350–500 cells/mm3) and HIV VL 
(500–9999 copies/ml) were no longer statistically significant in HIV/HCV coinfected 
patients, potentially due to the smaller number of patients within these categories.
When we stratified our model by baseline FIB-4 using a cutoff (median) value of 0.8, the 
risk estimates remained unchanged and statistically significant. The incidence of advanced 
fibrosis was 3.1 per 100 PYFU (95% CI 2.9–3.3) among patients with baseline FIB-4 ≥0.8 
and <1.45 compared with 1.4 per 100 PYFU (95% CI 1.3–1.6) among those with baseline 
FIB-4 <0.8.
We found comparable results when we examined advanced fibrosis measured by APRI >1.5 
(Table 3). HCV coinfection (aHR 1.9, 95% CI 1.7–2.1), HBV coinfection (aHR 1.6, 95% CI 
1.3–1.9), alcohol use disorder (aHR 1.3, 95% CI 1.1–1.4), diabetes (aHR 1.5, 95% CI 1.3–
1.8), CD4 count (for CD4 <100 cells/mm3, aHR 5.8, 95% CI 5.0–6.8) and HIV VL (for VL 
≥100,000 copies/ml, aHR 2.2, 95% CI 1.9–2.6) remained independent risk factors for 
fibrosis. Age was not associated with APRI in these models.
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 Interaction between CD4 count and HIV VL
We found a statistically significant interaction between CD4 count and HIV VL on the risk 
of progression to advanced liver fibrosis (aHR 1.31, 95% 1.03–1.67, P=0.03). Patients with a 
CD4 count <200 cells/mm3 had over three times the risk of progression to advanced fibrosis 
(aHR 3.3, 95% CI 2.7–4.0) compared to patients with a CD4 count ≥200 cells/mm3, and 
patients with detectable HIV VL (>500 copies/ml) were also at significantly higher risk of 
progression (aHR 1.7, 95% CI 1.5–2.0) than patients with undetectable HIV VL. Having 
both low CD4 count (<200 cells/mm3) and detectable HIV VL (≥500 copies/ml) resulted in 
having over seven-fold greater risk of liver disease progression (aHR 7.3, 95% CI 6.4–8.3).
 Secondary Analyses with Alcohol, BMI & Platelets
We found no effect modification of HCV or other factors by alcohol use disorder. BMI was 
not associated with fibrosis progression, and did not change the risk estimate associated with 
diabetes. The association between FIB-4 progression and HCV, HBV, diabetes, CD4 count 
and HIV VL remained significant when we repeated the analysis at different levels of 
baseline platelet count (data not shown).
 Discussion
In this study of over 14,000 HIV-infected individuals in care across the US with no more 
than minimal liver fibrosis at baseline, we found that nearly 10% progressed to advanced 
fibrosis during a median of 3 years of follow-up. The highest incidence of progression was 
seen in HIV-HCV coinfected patients who comprised 24% of those who progressed, 
consistent with previous studies of HIV-HCV coinfected patients that found progression to 
advanced fibrosis occurring in as few as 3–5 years–.
The large size and diversity of our study cohort, with over 61,000 person years of follow up, 
enabled us to determine the independent contribution of multiple factors to the progression 
of liver fibrosis from minimal to advanced disease among those with and without viral 
hepatitis. We found that HCV coinfection, HBV coinfection, alcohol use disorder and 
diabetes were independently associated with progression to advanced fibrosis even among 
patients with the lowest baseline FIB-4 scores. In addition, after controlling for known risk 
factors, patients with suboptimal control of HIV infection were at particular risk of 
progression to advanced fibrosis whether or not they had viral hepatitis. Our findings were 
similar whether advanced fibrosis was measured by FIB-4 or APRI.
The significant impact of HIV infection on the progression of liver disease, apart from viral 
hepatitis, is evidenced by the increasing risk of advanced fibrosis with greater exposure to 
each lower CD4 level of count and higher level of HIV viremia in both HIV monoinfected 
and HIV-HCV coinfected patients after controlling for other factors. Moreover, our study is 
the first to demonstrate a significant interaction between CD4 count and HIV VL beyond the 
impact of each factor alone such that having both a low CD4 count and detectable HIV VL 
resulted in more than seven-fold increase in the risk of liver disease progression.
Our findings concur with previous observations that HIV-infected patients with hepatitis B 
or C and lower CD4 counts appear to be at greater risk of decompensated liver disease, and 
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liver-related deaths., However, an association between lower CD4 count and liver fibrosis 
has been noted primarily in HIV-HCV coinfected cohorts,– and has not been examined as 
extensively across all CD4 levels over time, in conjunction with HIV VL or in HIV 
monoinfected patients.
A deleterious effect of HIV VL on liver disease has been suggested by data evaluating the 
impact of ART on liver outcomes. Discontinuation of ART has been shown to be associated 
with clinical decompensation in patients with early cirrhosis and maintenance of ART with a 
reduced risk of significant fibrosis and liver-related events,. In our study, ART-mediated viral 
suppression significantly reduced the risk of fibrosis progression in a cohort of patients with 
minimal fibrosis at baseline. Moreover we found direct evidence that exposure to HIV 
viremia over time is a major risk factor for fibrosis progression, even after adjusting for CD4 
count. These findings underscore the potential role of virus-mediated liver injury 
independent of immune depletion and exhaustion, which may explain why the combination 
of low CD4 and high HIV VL was particularly detrimental. There may be multiple 
mechanisms for this pathophysiology: HIV has been shown to infect and activate hepatic 
stellate cells, which play a key role in hepatic fibrogenesis., The virus can also induce 
hepatocyte death via the CXCR4 chemokine coreceptor and promote a pro-fibrotic state 
within the liver through the expression of proinflammatory cytokines and monocyte 
activation. Markers of hepatic fibrogenesis have been shown to be elevated in HIV-infected 
patients compared to uninfected patients, and correlated with HIV viral level.
Consistent with the literature,,,,, diabetes was a major predictor of progression to advanced 
fibrosis in our cohort. Notably diabetes remained a risk factor even after adjusting for HCV 
coinfection and BMI. The mechanism for this association remains unclear. Insulin resistance 
can promote non-alcoholic fatty liver disease, which has been implicated as a major cause of 
unexplained liver aminotransferase elevation and advanced fibrosis in HIV-infected patients,, 
and in contrast to some studies of HCV monoinfected patients, may do so in the absence of 
an elevated BMI.
Excessive alcohol use has been known to exacerbate liver disease in patients with chronic 
HCV monoinfection, however we as well as others,, did not detect effect modification of 
HCV coinfection by alcohol use disorder. Black race, present in 41% of those who 
progressed, was not associated with advanced fibrosis when controlling for HIV disease 
markers and other factors. In contrast to other studies, we did not find a protective effect of 
black race on the development of fibrosis.
This study has a number of limitations that should be acknowledged. While FIB-4 has been 
well validated in HIV-HCV coinfected populations, it has not been evaluated as extensively 
in HIV monoinfected patients. In addition, as a non-invasive marker for fibrosis, FIB-4 has 
only moderate discriminatory power for the different stages of fibrosis and modest positive 
predictive value for advanced liver disease. FIB-4 values may also fluctuate due to comorbid 
conditions, both intrahepatic (e.g. hepatic injury from alcohol, medications, opportunistic 
infections) and extrahepatic (e.g. sepsis), that may not represent fibrosis per se. We restricted 
our laboratory results to those obtained in the outpatient setting to mitigate these effects and 
the large sample size of our cohort likely offset this variability. Despite these limitations, 
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FIB-4 has been shown to predict liver-related outcomes such as hepatic decompensation and 
death, and to out-perform liver biopsy in this regard. It is possible that thrombocytopenia due 
to immune dysregulation or marrow suppression from advanced HIV disease rather than 
from liver disease resulted in FIB-4 elevation in some cases. Our results were unchanged 
when we stratified by platelet count suggesting that thrombocytopenia independent of liver 
disease was unlikely to account for our findings. In addition, among patients who had FIB-4 
progression, those with low CD4 count (<200 cells/mm3) were just as likely to have an 
elevated AST as those with CD4 count ≥200 cells/mm3 with median AST values at the end 
of follow-up (107 vs. 139 U/L respectively) that were not appreciably different. The same 
was true when examining AST by HIV VL (detectable or not), suggesting that HIV-
associated thrombocytopenia was not the sole contributor of elevated FIB-4.
In this large and diverse multicenter cohort of HIV-infected patients, we found that lower 
CD4 count and higher HIV viremia were significantly associated with progression to 
advanced hepatic fibrosis in a dose-dependent manner, independent of the risk associated 
with traditional factors including HCV and HBV coinfection, alcohol, and diabetes. In 
addition, individuals with both a low CD4 count and detectable HIV VL had an even greater 
risk of liver disease progression beyond the effect of each factor alone. Our findings provide 
additional support for the early diagnosis of HIV and suggest that early and effective 
treatment of HIV infection could mitigate liver disease progression. Further research is 
needed to better understand the mechanism and scope of HIV-mediated liver disease and to 
define optimal strategies to reduce liver disease progression among HIV-infected 
individuals.
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Table 1
Baselinea Demographic and Clinical Characteristics of the Study Population by Progression to Advanced 
Liver Fibrosis (FIB-4 ≥3.25)
Overall
(N=14,198)
Non-
Progressorsb
(n=12,812)
Progressorsb
(n=1,386)
Age, median years (IQR) 38 (31–45) 38 (31–44) 40 (34–46)
Sex, male 11,627 (82) 10,508 (82) 1119 (81)
Race
  White 6548 (46) 5927 (46) 621 (45)
  Black 4879 (34) 4315 (34) 564 (41)
  Hispanic 1988 (14) 1830 (14) 158 (11)
  Other 783 (6) 740 (6) 43 (3)
HIV Risk factor
  MSM 8227 (58) 7582 (59) 645 (47)
  Heterosexual 3635 (26) 3271 (26) 364 (26)
  IDU 1628 (11) 1348 (11) 280 (20)
  Other 708 (5) 611 (5) 97 (7)
Chronic hepatitis C 1666 (12) 1339 (10) 327 (24)
Chronic hepatitis B 521 (4) 434 (3) 87 (6)
Alcohol use disorder 1319 (9) 1119 (9) 200 (14)
Diabetes mellitus 530 (4) 456 (4) 74(5)
CD4, cells/mm3
  ≥500 5497 (39) 5129 (40) 368 (27)
  350–500 3237 (23) 2958 (23) 279 (20)
  200–349 3010 (21) 2703 (21) 307 (22)
  100–199 1420 (10) 1221 (10) 199 (14)
  <100 1034 (7) 801 (6) 233 (17)
HIV RNA level, copies/ml
  <500 8594 (61) 7940 (62) 654 (47)
  500–9999 2155 (15) 1924 (15) 231 (17)
  10,000–99,999 2511 (18) 2196 (17) 315 (23)
  ≥100,000 938 (7) 752 (6) 186 (13)
FIB-4, median (IQR) 0.8 (0.6–1.0) 0.8 (0.6–1.0) 1.0 (0.7–1.2)
aChronic hepatitis C, hepatitis B, alcohol use disorder, diabetes, CD4 count, HIV RNA level and FIB-4 represented baseline measurement within 
six months of study entry.
bAll comparisons between patients who progressed and those who did not were statistically significant to P <0.01 with exception of sex (P =0.2).
IQR, interquartile range; MSM, men who have sex with men; IDU, injection drug use.
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